Rigel(RIGL) - 2023 Q4 - Earnings Call Transcript

And lastly, R289, our IRAK1 and 4 inhibitor, is continuing to enroll its Phase 1b trial. We hope that this program demonstrates the potential of R289 to provide patients who have failed other agents with a much needed treatment option. We expect to have preliminary data from the first part of this trial late this year. With that, let me turn to Slide 25 to review the strategic efforts with MD Anderson. There are four patient populations that we and MD Anderson are particularly excited about for olutasidenib ...